Tetratherix (ASX:TTX) said the second stage of the TUTELA trial, a first in-human clinical investigation of the Tutelix hydrogel spacer, was initiated and patient recruitment is underway, according to a Monday Australian bourse filing.

Its Tegenix bone regeneration animal study implantation began, and the US Food and Drug Administration submission timing remains on track, it added.

Its TegenEOS animal study implementation is planned for the second quarter of fiscal year 2026.